Health Boards
This is a meta-analysis of 59 studies with up to 18,666 cases and 50,724 controls which quantifies the level of cardiovascular disease risk factors in patients with psoriasis.
Objectives:
To quantify the level of cardiovascular disease risk factors in order to provide additional data for the clinical management of the increased risk.
Methods:
This was a meta-analysis of observational studies with continuous outcome using random-effects statistics. A systematic search of studies published before 25 October 2012 was conducted using the databases Medline, EMBASE, International Pharmaceutical Abstracts, PASCAL and BIOSIS.
Results:
We included 59 studies with up to 18 666 cases and 50 724 controls. Psoriasis cases had a higher total cholesterol [weighted mean difference 8·83 mg dL−1, 95% confidence interval (CI) 2·94–14·72, P = 0·003 (= 0·23 mmol L−1)], higher low-density lipoprotein cholesterol [9·90 mg dL−1, 95% CI 1·56–18·20, P = 0·020 (= 0·25 mmol L−1)], higher triglyceride [16·32 mg dL−1, 95% CI 12·02–20·63, P < 0·001 (= 0·18 mmol L−1)], a higher systolic blood pressure (4·77 mmHg, 95% CI 1·62–7·92, P = 0·003), a higher diastolic blood pressure (2·99 mmHg, 95% CI 0·60–5·38, P = 0·014), higher body mass index (0·73 kg m−2, 95% CI 0·37–1·09, P < 0·001), higher waist circumference (3·61 cm, 95% CI 2·12–5·10, P < 0·001), higher fasting glucose [3·52 mg dL−1, 95% CI 0·64–6·41, P = 0·017 (= 0·20 mmol L−1)], higher nonfasting glucose [11·70 mg dL−1, 95% CI 11·24–12·15, P < 0·001 (= 0·65 mmol L−1)] and a higher HbA1c [1·09 mmol mol−1, 95% CI 0·87–1·31, P < 0·001 (= 2·2%)].
Conclusions:
From a preventive medicine perspective, the weighted mean differences between cases and controls are significant, and therefore relevant to the clinical management of patients with psoriasis.
Source: NO LINKS ALLOWED
Objectives:
To quantify the level of cardiovascular disease risk factors in order to provide additional data for the clinical management of the increased risk.
Methods:
This was a meta-analysis of observational studies with continuous outcome using random-effects statistics. A systematic search of studies published before 25 October 2012 was conducted using the databases Medline, EMBASE, International Pharmaceutical Abstracts, PASCAL and BIOSIS.
Results:
We included 59 studies with up to 18 666 cases and 50 724 controls. Psoriasis cases had a higher total cholesterol [weighted mean difference 8·83 mg dL−1, 95% confidence interval (CI) 2·94–14·72, P = 0·003 (= 0·23 mmol L−1)], higher low-density lipoprotein cholesterol [9·90 mg dL−1, 95% CI 1·56–18·20, P = 0·020 (= 0·25 mmol L−1)], higher triglyceride [16·32 mg dL−1, 95% CI 12·02–20·63, P < 0·001 (= 0·18 mmol L−1)], a higher systolic blood pressure (4·77 mmHg, 95% CI 1·62–7·92, P = 0·003), a higher diastolic blood pressure (2·99 mmHg, 95% CI 0·60–5·38, P = 0·014), higher body mass index (0·73 kg m−2, 95% CI 0·37–1·09, P < 0·001), higher waist circumference (3·61 cm, 95% CI 2·12–5·10, P < 0·001), higher fasting glucose [3·52 mg dL−1, 95% CI 0·64–6·41, P = 0·017 (= 0·20 mmol L−1)], higher nonfasting glucose [11·70 mg dL−1, 95% CI 11·24–12·15, P < 0·001 (= 0·65 mmol L−1)] and a higher HbA1c [1·09 mmol mol−1, 95% CI 0·87–1·31, P < 0·001 (= 2·2%)].
Conclusions:
From a preventive medicine perspective, the weighted mean differences between cases and controls are significant, and therefore relevant to the clinical management of patients with psoriasis.
Source: NO LINKS ALLOWED